Taisho Pharmaceutical Holdings Co., Ltd.
4581
Classement en actions
#3723
Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise... Taisho Pharmaceutical Holdings Co., Ltd. is a global healthcare enterprise involved in the comprehensive research, development, production, marketing, and distribution of both non-prescription (OTC) and ethical pharmaceutical products, serving markets in Japan and worldwide. The company's operations are divided into two principal divisions: the Self-Medication Operation Group and the Prescription Pharmaceutical Operation Group. The Self-Medication Group provides a diverse portfolio of consumer health products, including over-the-counter medicines, quasi-pharmaceuticals, food products, and general medical and hygiene items. Prominent brands within this segment include the Lipovitan energy drink series, Pabron cold and sinus remedies, RiUP hair re-growth solutions, Taisho Kampo gastrointestinal treatments, Colac laxatives, Naron and other pain relievers for fever, Preser hemorrhoid treatments, Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic-analgesic relief, Counterpain topical anti-inflammatory products, Vitacilina dermatological treatments, and VICKS cough suppressant throat lozenges and medicated drops. This division also encompasses real estate leasing, facility management, and hotel operations. Conversely, the Prescription Pharmaceutical Group specializes in ethical drugs such as Edirol, an active vitamin D3 agent for osteoporosis; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate for osteoporosis; Lusefi, an agent for type 2 diabetes mellitus; and LOQOA, a transdermal anti-inflammatory analgesic. This segment is also engaged in ongoing drug development, primarily focusing on therapeutic areas like central nervous system disorders, infectious diseases, metabolic conditions, and orthopedic ailments. Additionally, Taisho Pharmaceutical Holdings supplies raw materials for pharmaceutical and quasi-drug manufacturing, alongside offering health foods and skincare products. The company was established in Tokyo, Japan, in 1912, where its headquarters remain.
Prix de l'action
$54.31
Dernière synchronisation: 2024-04-08
Capitalisation boursière
$4.45B
Changement (1 jour)
-4.14%
Changement (1 an)
0.00%
Pays
JP
Échange Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Catégorie
Healthcare
Nombre d'actions en circulation pour Taisho Pharmaceutical Holdings Co., Ltd. (4581)
Nombre d'actions en circulation au October 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Taisho Pharmaceutical Holdings Co., Ltd., le nombre actuel d'actions en circulation est de 0. À la fin de October 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Taisho Pharmaceutical Holdings Co., Ltd. (4581) de 2006 à 2026
Actions en circulation à la fin de chaque année
| Année | Actions en circulation | Changez |
|---|---|---|
| 2023 | 81.98M | 0.66% |
| 2022 | 81.44M | 2.04% |
| 2021 | 79.82M | 0.00% |
| 2020 | 79.82M | 0.00% |
| 2019 | 79.82M | -0.09% |
| 2018 | 79.89M | -0.02% |
| 2017 | 79.91M | -1.24% |
| 2016 | 80.91M | -0.19% |
| 2015 | 81.07M | -0.02% |
| 2014 | 81.09M | 0.21% |
| 2013 | 80.92M | -1.60% |
| 2012 | 82.23M | -1.88% |
| 2011 | 83.81M | -2.54% |
| 2010 | 85.99M | -2.41% |
| 2009 | 88.12M | -1.32% |
| 2008 | 89.29M | -2.51% |
| 2007 | 91.60M | -0.95% |
| 2006 | 92.47M | 0.00% |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise | Actions en circulation | Différence | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | - |
IN
|
